A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors.
Jianbing LiuLinlin SongShaoli LiuShuai ZhaoQiao JiangBaoquan DingPublished in: Angewandte Chemie (International ed. in English) (2018)
Multidrug resistance (MDR) is a major obstacle in the clinical treatment of cancer. Herein, a facile strategy is reported to construct a versatile DNA nanostructure as a co-delivery vector of RNA interference (RNAi) and chemodrugs to combat multidrug-resistant tumor (MCF-7R) in vitro and in vivo. In the tailored nanocarrier, two linear small hairpin RNA (shRNA) transcription templates targeting MDR-associated genes (gene of P-glycoprotein, a typical drug efflux pump; and gene of survivin, a representative anti-apoptotic protein) are precisely organized in the chemodrug (doxorubicin, DOX) pre-loaded DNA origami. With the incorporation of active targeting and controlled-release elements, these multifunctional DNA nanocarriers can successfully enter the target MCF-7R cells and synergistically inhibit tumor growth without apparent systemic toxicity. This tailored DNA nanoplatform, which combines RNAi therapy and chemotherapy, provides a new strategy for the treatment of multidrug-resistant tumors.
Keyphrases
- multidrug resistant
- cancer therapy
- drug delivery
- circulating tumor
- cell free
- drug resistant
- single molecule
- gram negative
- acinetobacter baumannii
- nucleic acid
- klebsiella pneumoniae
- genome wide
- smoking cessation
- drug release
- magnetic resonance imaging
- cell death
- copy number
- genome wide identification
- emergency department
- transcription factor
- cell proliferation
- locally advanced
- cell cycle arrest
- quantum dots
- combination therapy
- genome wide analysis
- escherichia coli
- lymph node metastasis
- radiation therapy
- dna methylation
- computed tomography
- small molecule
- binding protein
- diffusion weighted imaging
- cross sectional
- squamous cell